CD8A and neoplasm: They stimulate a CD4+ T cell-dependent delayed-type hypersensitivity reaction, promote robust CD4+ and CD8+ T cell proliferation, and elicit CD8+ T cell-dependent target cell killing and anti-tumor immunity.